Who Owns Immunocore Company?

Who Owns Immunocore?

Immunocore's ownership structure is a key factor in its strategic direction and accountability within the biopharmaceutical industry. The company's IPO in February 2021 significantly altered its ownership, bringing in substantial capital for pipeline advancement.

Understanding who holds stakes in Immunocore provides insight into its governance and future development. This includes examining founder holdings, major institutional investors, and the broader public shareholder base.

As of August 2025, Immunocore's market capitalization is between $1.65 billion and $1.77 billion USD. The company's lead product, KIMMTRAK, is approved for unresectable or metastatic uveal melanoma, demonstrating its commercial viability. The company's pioneering T-cell receptor (TCR) research, originating from Oxford University, underpins its development of ImmTAC molecules, designed to target cancer cells. The Immunocore BCG Matrix is part of their innovative approach.

The origins of Immunocore are deeply rooted in academic research, specifically the T-cell receptor (TCR) technology developed at Oxford University. This foundational work led to the establishment of Avidex Ltd. in 1999, which was later acquired by MediGene AG in 2006. Immunocore itself was officially launched in 2008 as a spinout from MediGene AG, building upon the pioneering TCR advancements.

Founding Visionaries

Key figures in Immunocore's inception include Bent Jakobsen, the scientific mind behind the core TCR technology, and James Noble, who transitioned from CEO of Avidex to lead Immunocore as its founding CEO.

Early Genesis

The company's early operations were supported by venture funding secured by Avidex. Following its demerger in 2008, Immunocore continued to grow with initial backing and subsequent significant private investment.

Landmark Financing

A pivotal moment for Immunocore was its $320 million Series A financing in July 2015, which was then the largest for a private life sciences firm in Europe. This funding round attracted major investors.

Key Early Investors

Prominent participants in the Series A round included Fidelity Management & Research Company, Woodford Investment Management, Malin Corporation, Eli Lilly and Company, and RTW Investments, underscoring strong early confidence in the company's potential.

Further Investment Milestones

The company secured an additional $40 million from the Bill and Melinda Gates Foundation in September 2017. Subsequent private rounds, including a $130 million Series B in March 2020 led by General Atlantic and a $75 million Series C in January 2021 with BlackRock joining, further fueled its development.

Founders and Co-Founders

Beyond Jakobsen and Noble, other co-founders instrumental in Immunocore's establishment are George Edward Silvanus Robinson, Nicholas John Cross, and George Kelly Martin, all contributing to the company's foundational structure.

The early ownership structure of Immunocore was shaped by its origins as a spinout and its subsequent success in attracting substantial venture capital and private equity. While specific founder equity splits at inception are not publicly disclosed, the company's trajectory was significantly influenced by its ability to secure major funding rounds. These early investments were critical in validating the founding team's vision and enabling the company to advance its innovative immunotherapies, impacting its overall Immunocore ownership landscape.

Complete Immunocore Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

The ownership journey of Immunocore significantly shifted with its Initial Public Offering (IPO) on February 5, 2021. This transition from a private entity to a publicly traded company on the Nasdaq Global Select Market under the ticker 'IMCR' marked a new era for its share distribution and stakeholder landscape.

Following its IPO, Immunocore's ownership structure is predominantly characterized by significant institutional investment. As of August 2025, institutional investors hold a commanding majority of the company's shares, with estimates indicating holdings between approximately 84.50% and 94.07%. Insiders represent a smaller fraction, holding around 5.23%, while public companies and individual investors make up the remainder, though their exact percentage can vary depending on how institutional holdings are categorized. Key institutional shareholders include prominent firms such as T. Rowe Price Investment Management, Inc., Wellington Management Group Llp, RTW Investments, LP, FMR Llc, Vanguard Health Care Fund, PRIMECAP Management Co., Baker Bros. Advisors Lp, General Atlantic Service Company, L.P., Point72 Asset Management, L.P., TD Asset Management, Inc., and BlackRock. Additionally, Eli Lilly & Co. maintains a notable stake of 5.07%. These holdings reflect the evolving confidence in Immunocore's strategic direction and the commercialization of its therapies, such as KIMMTRAK. Understanding the Brief History of Immunocore provides context for this ownership evolution.

Key Immunocore Shareholders

Institutional investors are the primary holders of Immunocore stock, reflecting strong confidence in the company's market position and growth prospects.

• Institutional Ownership: Approximately 84.50% - 94.07% (as of August 2025)
• Insider Ownership: Approximately 5.23%
• Notable Institutional Investors: T. Rowe Price, Wellington Management, RTW Investments, FMR Llc, Vanguard Health Care Fund, PRIMECAP, Baker Bros. Advisors, General Atlantic, Point72, TD Asset Management, BlackRock.
• Significant Corporate Stakeholder: Eli Lilly & Co. (5.07%)

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The governance of Immunocore is overseen by its board of directors, a group responsible for strategic direction and corporate oversight. Sir John Bell chairs this board, with Bahija Jallal, the CEO since January 2019, also serving as a director. Other key members include Lily Margaret Hepworth and Francoise Pauline Webster, an independent director. The board also features notable figures like William Pao and Peter J. Ratcliffe, bringing extensive experience from the pharmaceutical and research sectors.

The composition of the board highlights a blend of internal leadership, such as the CEO, and external expertise from independent directors and prominent figures in the scientific and business communities. As a publicly traded company on Nasdaq, Immunocore's voting power is significantly influenced by its shareholder base. As of August 2025, institutional investors hold a substantial portion of the company's stock, estimated at up to 94.07%, indicating their considerable collective influence on corporate decisions. There have been no significant public reports of proxy contests or activist campaigns that have altered the company's established decision-making structures in recent years.

Understanding Immunocore's Shareholder Influence

Institutional investors command a significant majority of Immunocore's stock, suggesting their substantial impact on the company's direction. This concentration of ownership is a key factor in understanding Immunocore company ownership.

• Institutional ownership reached up to 94.07% as of August 2025.
• This high percentage indicates strong influence from major investment firms.
• The board of directors oversees strategic decisions, guided by shareholder interests.
• Understanding Immunocore investors is crucial for grasping its ownership structure.
• The company's public trading status on Nasdaq facilitates this investor oversight.

Immunocore Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Following its February 2021 IPO, Immunocore's ownership landscape has evolved, marked by key financing events and a strong trend towards institutional backing. This period reflects the dynamic nature of biotechnology company ownership.

The company's ownership profile is heavily influenced by institutional investors, who held between 84.50% and 94.07% of its shares as of August 2025. This significant institutional stake indicates strong confidence from major funds and asset managers in Immunocore's strategic direction and pipeline. While founder dilution is a common occurrence after public offerings and subsequent funding rounds, there have been no reported large-scale share buybacks or secondary offerings beyond the initial IPO and the 2022 private placement. The company's leadership, with Bahija Jallal serving as CEO since January 2019, has remained consistent, suggesting a stable operational focus through 2025, supported by existing cash reserves, KIMMTRAK revenue, and the capital from the private placement.

Institutional Investor Dominance

Institutional investors represent the vast majority of Immunocore's shareholders. This trend highlights the sector's appeal to large asset managers and funds.

Strategic Capital Infusion

The 2022 private placement, which included participation from existing investors, was crucial for advancing Immunocore's clinical programs. This funding supports ongoing development in oncology and infectious diseases.

Consistent Leadership and Focus

With stable leadership, the company is focused on its operational plans through 2025. This stability is often viewed favorably by investors, especially within the volatile biotech market.

Ownership Trends in Biotech

Immunocore's ownership trends align with broader patterns in the biotechnology sector, characterized by significant institutional investment. Understanding these dynamics is key to grasping the Competitors Landscape of Immunocore.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE